Medical technology company RaySearch Laboratories AB (STO:RAYB) announced on Thursday that Anderson Regional Cancer Centre in Meridian, Mississippi, US, has treated its first patient using the combination of RaySearch's treatment planning system (TPS) RayStation and Accuray Incorporated's TomoTherapy Treatment Delivery System.
Reportedly, this is the first-ever treatment in the US using the two innovative technologies.
This first treatment combining RayStation and TomoTherapy System at Anderson Regional Cancer Centre was successfully administered to treat a prostate cancer patient. Moving forward, the centre plans to use this combination of TPS and radiation treatment delivery system to also treat cancers of the breast, lung and head and neck.
According to the company, Anderson Regional Cancer Centre first began using RayStation in 2013 with its conventional linear accelerators, which provided significant benefits for workflow and patient treatments. The centre then added the TomoTherapy System, a highly advanced radiation treatment. This centre has worked closely with RaySearch and Accuray to join the technologies and is now using RayStation for all radiation treatment planning, which is providing substantial gains in efficiency.
Accuray Incorporated is a radiation oncology company.
RaySearch Laboratories develops software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare, the next-generation oncology information system, worldwide.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review